Vanda Pharmaceuticals Inc (NAS:VNDA)
$ 5.04 -0.11 (-2.14%) Market Cap: 293.87 Mil Enterprise Value: -68.03 Mil PE Ratio: 0 PB Ratio: 0.54 GF Score: 81/100

Vanda Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript

May 10, 2022 / 11:00PM GMT
Release Date Price: $10.22 (+4.93%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

The afternoon session of the BofA Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here at BofA. We're thrilled today to have Vanda Pharmaceuticals, and speaking on behalf of Vanda is CFO, Kevin Moran. Kevin?

Kevin Patrick Moran
Vanda Pharmaceuticals Inc. - Senior VP, CFO & Treasurer

Good afternoon, everyone, and thank you very much, Geoff, for the introduction and the invitation. Very excited to share our progress with everyone here.

Great. Here are our forward-looking statements that we'd like for folks to review and be aware of.

So Vanda has 2 commercialized products, HETLIOZ and Fanapt. HETLIOZ comes in 2 forms, oral capsules and liquid formulation. Oral capsules are approved in the U.S. and Europe for the treatment of Non-24-hour sleep wake disorder. HETLIOZ oral capsules and HETLIOZ LQ, the liquid formulation, are also approved for the treatment of nighttime sleep disturbances in adults and children, respectively,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot